Compare LAC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | PHAT |
|---|---|---|
| Founded | 2023 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 969.8M |
| IPO Year | 2023 | 2019 |
| Metric | LAC | PHAT |
|---|---|---|
| Price | $3.01 | $8.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $6.14 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 9.2M | 1.5M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $2.53 | $8.03 |
| 52 Week High | $10.52 | $18.31 |
| Indicator | LAC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 34.58 |
| Support Level | N/A | $8.78 |
| Resistance Level | $4.04 | $13.17 |
| Average True Range (ATR) | 0.14 | 0.67 |
| MACD | 0.05 | -0.30 |
| Stochastic Oscillator | 53.57 | 15.83 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.